METACRINE INC (MTCR) Stock Price, Quote, News and Overview
NASDAQ:MTCR - Nasdaq - US59101E1038 - Common Stock - Currency: USD
MTCR Quote, Performance and Key Statistics
0.4949
0 (-0.02%)
The current stock price of MTCR is 0.4949 USD. In the past month the price increased by 8.77%. In the past year, price increased by 6.5%.
MTCR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MTCR
Company Profile
Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The company went IPO on 2020-09-16. The firm is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The firm's program targets the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. The firm's product candidates include MET409 and MET642. The firm is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease characterized by excess liver fat, inflammation and fibrosis. The firm is focused on the farnesoid X receptor (FXR), which is central to modulating gastrointestinal (GI) and liver diseases. The firm is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). Its Inflammatory Bowel Disease (IBD) is a global health issue and is thought to occur due to a maladaptive immune response to gut microbes. UC and Crohn’s disease are the two primary types of IBD.
Company Info
METACRINE INC
4225 Executive Square, Suite 600
San Diego CALIFORNIA 92121 US
CEO: Preston Klassen
Employees: 10
Company Website: https://www.metacrine.com
Phone: 18583697800.0
METACRINE INC / MTCR FAQ
What is the stock price of METACRINE INC today?
The current stock price of MTCR is 0.4949 USD. The price decreased by -0.02% in the last trading session.
What is the ticker symbol for METACRINE INC stock?
The exchange symbol of METACRINE INC is MTCR and it is listed on the Nasdaq exchange.
On which exchange is MTCR stock listed?
MTCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for METACRINE INC stock?
7 analysts have analysed MTCR and the average price target is 0.51 USD. This implies a price increase of 3.05% is expected in the next year compared to the current price of 0.4949. Check the METACRINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is METACRINE INC worth?
METACRINE INC (MTCR) has a market capitalization of 21.07M USD. This makes MTCR a Nano Cap stock.
How many employees does METACRINE INC have?
METACRINE INC (MTCR) currently has 10 employees.
What are the support and resistance levels for METACRINE INC (MTCR) stock?
METACRINE INC (MTCR) has a support level at 0.43 and a resistance level at 0.51. Check the full technical report for a detailed analysis of MTCR support and resistance levels.
Should I buy METACRINE INC (MTCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MTCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MTCR, evaluating the profitability, health, valuation and growth aspects
- METACRINE INC (MTCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- METACRINE INC (MTCR) Sales and EPS estimates to see what analysts future expectations are.
- METACRINE INC (MTCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- METACRINE INC (MTCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- METACRINE INC (MTCR) Stock Chart to make your own analysis
- METACRINE INC (MTCR) Latest news and press-releases to stay up to date.
Does METACRINE INC (MTCR) stock pay dividends?
MTCR does not pay a dividend.
When does METACRINE INC (MTCR) report earnings?
METACRINE INC (MTCR) will report earnings on 2023-03-28, after the market close.
What is the Price/Earnings (PE) ratio of METACRINE INC (MTCR)?
METACRINE INC (MTCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.91).
MTCR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MTCR. When comparing the yearly performance of all stocks, MTCR is one of the better performing stocks in the market, outperforming 86.79% of all stocks.
MTCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MTCR. The financial health of MTCR is average, but there are quite some concerns on its profitability.
MTCR Financial Highlights
Over the last trailing twelve months MTCR reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS increased by 69.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.34 |
MTCR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to MTCR. The Buy consensus is the average rating of analysts ratings from 7 analysts.